BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
151 hedge funds and large institutions have $228M invested in bluebird bio in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
42% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 45
59% less call options, than puts
Call options by funds: $1.84M | Put options by funds: $4.53M
Holders
151
Holding in Top 10
1
Calls
$1.84M
Puts
$4.53M
Top Buyers
| 1 | +$18.1M | |
| 2 | +$7.74M | |
| 3 | +$6.48M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.45M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.38M |
Top Sellers
| 1 | -$46.9M | |
| 2 | -$10M | |
| 3 | -$3.82M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.5M |
| 5 |
Rafferty Asset Management
New York
|
-$2.97M |